|
Gene: PRRC2B |
Gene summary for PRRC2B |
Gene summary. |
Gene information | Species | Human | Gene symbol | PRRC2B | Gene ID | 84726 |
Gene name | proline rich coiled-coil 2B | |
Gene Alias | BAT2L | |
Cytomap | 9q34.13 | |
Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | Q5JSZ5 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
84726 | PRRC2B | HTA11_546_2000001011 | Human | Colorectum | AD | 4.47e-11 | -7.71e-01 | -0.0842 |
84726 | PRRC2B | HTA11_9341_2000001011 | Human | Colorectum | SER | 1.24e-02 | -7.71e-01 | -0.00410000000000005 |
84726 | PRRC2B | HTA11_7862_2000001011 | Human | Colorectum | AD | 5.02e-09 | -7.71e-01 | -0.0179 |
84726 | PRRC2B | HTA11_866_3004761011 | Human | Colorectum | AD | 5.01e-29 | -7.71e-01 | 0.096 |
84726 | PRRC2B | HTA11_4255_2000001011 | Human | Colorectum | SER | 1.25e-04 | -7.71e-01 | 0.0446 |
84726 | PRRC2B | HTA11_9408_2000001011 | Human | Colorectum | AD | 3.47e-03 | -7.71e-01 | 0.0451 |
84726 | PRRC2B | HTA11_8622_2000001021 | Human | Colorectum | SER | 1.50e-07 | -7.71e-01 | 0.0528 |
84726 | PRRC2B | HTA11_7663_2000001011 | Human | Colorectum | SER | 2.46e-05 | -7.71e-01 | 0.0131 |
84726 | PRRC2B | HTA11_10623_2000001011 | Human | Colorectum | AD | 1.54e-08 | -7.71e-01 | -0.0177 |
84726 | PRRC2B | HTA11_6801_2000001011 | Human | Colorectum | SER | 4.28e-04 | -7.71e-01 | 0.0171 |
84726 | PRRC2B | HTA11_10711_2000001011 | Human | Colorectum | AD | 1.70e-18 | -7.71e-01 | 0.0338 |
84726 | PRRC2B | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.13e-42 | -7.71e-01 | 0.0674 |
84726 | PRRC2B | HTA11_6818_2000001011 | Human | Colorectum | AD | 7.28e-09 | -7.71e-01 | 0.0112 |
84726 | PRRC2B | HTA11_11156_2000001011 | Human | Colorectum | AD | 2.94e-02 | -7.71e-01 | 0.0397 |
84726 | PRRC2B | HTA11_6818_2000001021 | Human | Colorectum | AD | 1.68e-14 | -7.71e-01 | 0.0588 |
84726 | PRRC2B | HTA11_99999970781_79442 | Human | Colorectum | MSS | 3.61e-07 | -3.94e-01 | 0.294 |
84726 | PRRC2B | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.39e-03 | -2.92e-01 | 0.3005 |
84726 | PRRC2B | F007 | Human | Colorectum | FAP | 2.30e-02 | -3.47e-01 | 0.1176 |
84726 | PRRC2B | A015-C-203 | Human | Colorectum | FAP | 6.91e-28 | -1.55e-01 | -0.1294 |
84726 | PRRC2B | A014-C-040 | Human | Colorectum | FAP | 4.53e-02 | -6.64e-02 | -0.1184 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PRRC2B | SNV | Missense_Mutation | c.2342N>T | p.Ser781Phe | p.S781F | Q5JSZ5 | protein_coding | deleterious(0.01) | benign(0.007) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
PRRC2B | SNV | Missense_Mutation | c.5326N>A | p.Asp1776Asn | p.D1776N | Q5JSZ5 | protein_coding | deleterious(0.02) | probably_damaging(0.998) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
PRRC2B | SNV | Missense_Mutation | c.1955C>A | p.Pro652Gln | p.P652Q | Q5JSZ5 | protein_coding | deleterious(0) | probably_damaging(0.942) | TCGA-AO-A03P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | letrozole | PD | |
PRRC2B | SNV | Missense_Mutation | novel | c.283G>T | p.Asp95Tyr | p.D95Y | Q5JSZ5 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AO-A0J4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
PRRC2B | SNV | Missense_Mutation | c.1774C>T | p.Pro592Ser | p.P592S | Q5JSZ5 | protein_coding | tolerated(0.16) | benign(0.007) | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | |
PRRC2B | SNV | Missense_Mutation | rs200364610 | c.101N>G | p.Ala34Gly | p.A34G | Q5JSZ5 | protein_coding | deleterious(0) | benign(0.387) | TCGA-B6-A0I1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PRRC2B | SNV | Missense_Mutation | c.4274N>A | p.Arg1425Lys | p.R1425K | Q5JSZ5 | protein_coding | deleterious(0) | probably_damaging(0.978) | TCGA-BH-A0DX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR | |
PRRC2B | SNV | Missense_Mutation | c.568N>A | p.Val190Ile | p.V190I | Q5JSZ5 | protein_coding | tolerated(0.08) | benign(0.339) | TCGA-C8-A12Z-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
PRRC2B | SNV | Missense_Mutation | c.2587N>A | p.Glu863Lys | p.E863K | Q5JSZ5 | protein_coding | tolerated(0.2) | benign(0.024) | TCGA-D8-A1JK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PRRC2B | SNV | Missense_Mutation | c.806N>C | p.Met269Thr | p.M269T | Q5JSZ5 | protein_coding | tolerated(0.16) | benign(0.039) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |